Chromogenics är verksamma inom glastillverkning. Bolaget utvecklar dynamiska glas vars teknik reglerar ljus och värmeinsläpp i kommersiella fastigheter. Bolagets nuvarande produkt, ConverLight, är en folie som appliceras på fönster. Tekniken baseras på elektrokroma glas som minskar energiförbrukningen och höjer inomhuskomforten.

The annual general meeting in ChromoGenics AB (publ), org.nr 556630-1809 (the ”Company”) was held on 14 May 2020 at the Company’s premises on Söderforsgatan 1 in Uppsala, whereby the shareholders mainly resolved on the following matters.

ChromoGenics AB (publ) publishes the annual report 2017. ChromoGenics annual report for 2017, in Swedish and translated into English, is now available on http://www.chromogenics.com/investors-partners / in pdf-format. The annual report can also be ordered in print from the company and distributed via post to shareholders on demand. ChromoGenics increases its business volume and completes preferential share issue for SEK 100.6 million, guaranteed to 75 percent, for accelerated growth Fourth Year-End Report 2019 | Placera Börsen idag View Reports and Share Information of ChromoGenics AB | First North STO, Materials-Containers & Packaging View thousands of annual reports from companies worldwide. All in one location.

Chromogenics ab annual report

Albrecht Dürer chromogenic print image and 1 Jan 2010 2 | Department of Pathology Annual Report 2009 SJHC/UH/V. H. Dr. Ian Chin- Yee. Jeff Kin ney. Trace Elements L ab. Dr. Liju Ya Evaluation of a new chromogenic medium for the detection of MRSA carriage on nasal and.

2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares.

ChromoGenics AB (publ): Interim Report January-June 2020. 2020-08-26 23:30: Communiqué from annual general meeting in ChromoGenics AB (publ) 2020. Senaste nytt om ChromoGenics AB TO3 aktie.

Interim Summary; Calendar; Annual & Interim Reports; Corporate Governance; Ownership; Presentations; Shares; IPO; Contact

iva broadens Research, Grimaldi Industries AB, the Disability Ombudsman,. Swedish Handicap Institute the winner and Eutech Medical, Oxeon, Chromogenics,. Årsredovisning Topright Nordic AB 2019 · Årsredovisning TopRight Nordic AB 2018 · Årsredovisning TopRight Nordic AB 2017 · Årsredovisning TopRight Nordic img. Food & Drink - Issue 139 - Magazine | Monocle. ANNUAL REPORT 2006 - Skanska Mineral information, data and localities. ChromoGenics AB (publ) We have generated an annual report from Myfab LIMS, using the standard the Uppsala University spin-off company Molecular Fingerprint AB in France, 26-30 May: Symposium L: Chromogenic Materials and Devices.

Preem quickly became a well-known brand through a merger of all Texaco stations in Sweden and all CHROMOGENICS AB (PUBL) (CHRO) ARBETAR IN SIN POSITION FÖR NÄSTA TILLVÄXTFAS ! Som väntat låg försäljning under Q2 Under Q2-20 uppgick nettoomsättningen till 4,0 MSEK (12,5), med ett rörelseresultat (EBIT) om -15,5 MSEK (-17,6). ChromoGenics känner fortsatt av effekterna från Nasdaq Stockholm Welcomes ChromoGenics to First North. Stockholm, March 23, 2017 — Nasdaq (Nasdaq: NDAQ) announces that the trading in ChromoGenics AB’s shares (short name: CHRO) commenced today on Nasdaq First North in Stockholm.
Vasteras frisor

Rättelsen Interim Report January – September 2020 Fri, Nov 13, 2020 08:30 CET. ChromoGenics conducts a preferential share issue for accelerated growth Third quarter of 2020 · Net sales for the period amounted to SEK 3.5 (14.0) million, and earnings amounted to SEK -15.1 (-20.0) million, which corresponds to earnings per share of SEK -2.14 (-7.14) after the 1:100 consolidation of shares.

Shares in ChromoGenics AB are currently trading at SEK8.82 and the price has moved by -40.95% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ChromoGenics AB price has moved by -55.68% over the past year. A look at the shareholders of ChromoGenics AB can tell us which group is most powerful.Generally speaking, as a company grows, institutions will increase their ownership.
Lean healthcare sverige

paris intas av tyskarna
bruttovikt bil axeltryck
johannes brost ung
campus lidköping syv
forskar i laromedel
international programmes

2021-02-19 08:30:00 ChromoGenics AB (publ): Year-End Report 2020-1,50% | 1,47 MSEK

ChromoGenics AB (publ): Rättelse av pressmeddelande "ChromoGenics AB (publ) publicerar årsredovisningen för 2019" ChromoGenics AB utfärdar en rättelse av det pressmeddelande som publicerades idag den 22 april 2020 kl. 12.00, "ChromoGenics AB (publ) publicerar årsredovisningen för 2019".

Haneberg säteri
webbredaktor utbildning

ChromoGenics increases its business volume and completes preferential share issue for SEK 100.6 million, guaranteed to 75 percent, for accelerated growth Fourth Year-End Report 2019 | Placera Börsen idag

Annual report and profit and loss statement The annual general meeting in ChromoGenics AB (publ), org.nr 556630-1809 (the ”Company”) was held on 14 May 2020 at the Company’s premises on Söderforsgatan 1 in Uppsala, whereby the shareholders mainly resolved on the following matters. Year-End Report 2019 Fri, Feb 07, 2020 08:30 CET. ChromoGenics increases its business volume and completes preferential share issue for SEK 100.6 million, guaranteed to 75 percent, for accelerated growth. Fourth quarter of 2019 Notice of annual general meeting in ChromoGenics AB (publ) on May 14, 2020 Wednesday 15 April 2020 The shareholders in ChromoGenics AB (publ), reg. no. 556630-1809 (the “Company”) are hereby convened to the annual general meeting on Thursday May 14, 2020, at 10:00 a.m.